These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 17934363)

  • 41. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.
    George JN; Woolf SH; Raskob GE; Wasser JS; Aledort LM; Ballem PJ; Blanchette VS; Bussel JB; Cines DB; Kelton JG; Lichtin AE; McMillan R; Okerbloom JA; Regan DH; Warrier I
    Blood; 1996 Jul; 88(1):3-40. PubMed ID: 8704187
    [No Abstract]   [Full Text] [Related]  

  • 42. Current therapies in primary immune thrombocytopenia.
    Pels SG
    Semin Thromb Hemost; 2011 Sep; 37(6):621-30. PubMed ID: 22102265
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Idiopathic thrombocytopenic purpura: beyond consensus.
    Medeiros D; Buchanan GR
    Curr Opin Pediatr; 2000 Feb; 12(1):4-9. PubMed ID: 10676767
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current options for the treatment of idiopathic thrombocytopenic purpura.
    Arnold DM; Kelton JG
    Semin Hematol; 2007 Oct; 44(4 Suppl 5):S12-23. PubMed ID: 18096468
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Approach to the investigation and management of immune thrombocytopenic purpura in children.
    Blanchette V; Carcao M
    Semin Hematol; 2000 Jul; 37(3):299-314. PubMed ID: 10942224
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predicting response to splenectomy in children with immune thrombocytopenic purpura.
    Wood JH; Partrick DA; Hays T; Ziegler MM
    J Pediatr Surg; 2010 Jan; 45(1):140-4; discussion 144. PubMed ID: 20105594
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An analysis of outcomes and treatment costs for children undergoing splenectomy for chronic immune thrombocytopenia purpura.
    Gwilliam NR; Lazar DA; Brandt ML; Mahoney DH; Wesson DE; Mazziotti MV; Nuchtern JG; Lee TC
    J Pediatr Surg; 2012 Aug; 47(8):1537-41. PubMed ID: 22901913
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune thrombocytopenia in adults: an update.
    Thota S; Kistangari G; Daw H; Spiro T
    Cleve Clin J Med; 2012 Sep; 79(9):641-50. PubMed ID: 22949345
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of immune thrombocytopenia: a retrospective study of 40 patients].
    Audia S; Lakomy D; Guy J; Leguy-Seguin V; Berthier S; Aho S; Lorcerie B; Bonnotte B
    Rev Med Interne; 2010 May; 31(5):337-44. PubMed ID: 20409619
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Twenty years experience with treatment of idiopathic thrombocytopenic purpura in a single department: results in 490 cases.
    Schiavotto C; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):22-8. PubMed ID: 8039754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.
    Arnold DM; Dentali F; Crowther MA; Meyer RM; Cook RJ; Sigouin C; Fraser GA; Lim W; Kelton JG
    Ann Intern Med; 2007 Jan; 146(1):25-33. PubMed ID: 17200219
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura.
    Kalpatthi R; Bussel JB
    Curr Opin Pediatr; 2008 Feb; 20(1):8-16. PubMed ID: 18197033
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Use of rituximab in resistant thrombocytopenic purpura].
    Zambrano-Velarde MA; de la O-Peña D; Chávez-Peña Q; Bedolla-Barajas M
    Rev Med Inst Mex Seguro Soc; 2012; 50(2):203-8. PubMed ID: 22882991
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The epidemiology of immune thrombocytopenic purpura.
    Fogarty PF; Segal JB
    Curr Opin Hematol; 2007 Sep; 14(5):515-9. PubMed ID: 17934361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura.
    Clausen MR; Segel E; Brandsborg M; d'Amore F
    Eur J Haematol; 2011 Mar; 86(3):256-9. PubMed ID: 21166717
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review.
    Vesely SK; Perdue JJ; Rizvi MA; Terrell DR; George JN
    Ann Intern Med; 2004 Jan; 140(2):112-20. PubMed ID: 14734334
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of immune thrombocytopenic purpura in children: potential role of novel agents.
    Bredlau AL; Semple JW; Segel GB
    Paediatr Drugs; 2011 Aug; 13(4):213-23. PubMed ID: 21692546
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy, safety, and dose response of intravenous anti-D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children.
    Freiberg A; Mauger D
    Semin Hematol; 1998 Jan; 35(1 Suppl 1):23-7. PubMed ID: 9523746
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunoglobulin anti-D for treatment of chronic ITP in children.
    Iacobini M; Duse M; Antonetti L; Smacchia MP; Schiavetti A
    Pediatr Blood Cancer; 2010 Dec; 55(7):1435. PubMed ID: 20981698
    [No Abstract]   [Full Text] [Related]  

  • 60. Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.
    Moulis G; Lapeyre-Mestre M; Mahévas M; Montastruc JL; Sailler L
    Am J Hematol; 2015 Apr; 90(4):301-5. PubMed ID: 25557586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.